PubMed Health⌕ Search

Biomedical subjects

H Dietzfelbinger

Publications and source records attributed to H Dietzfelbinger.

27 records · Page 2Linked to original sources
PubMed1979

[Comparison of bio-availability, antianaemic efficacy, tolerance and drug costs in oral iron(II) and iron(III) preparations (author's transl)].

In addition to a clinical study which investigated the bio-availability of three oral iron preparations S, L and X by using postabsorption serum iron concentration curves, the same drugs were compared in order to study their antianaemic efficacy, tolerance and drug costs arising during and iron therapy. Moreover, these iron drugs were related to other current clinical reports. Within all three iron preparations a very good correlation was found between bio-availability and haematopoietic efficacy: The very good absorbability of the bivalent quick release stick capsule preparation S (= 100%) corresponded with a very good capacity of haemoglobin regeneration (2,6 +/- 0,4 g Hb/1/day) whereas due to a very low absorbability (10% to 16%) the antianaemic efficacy of both iron(III) preparations L and X had to be rated as moderate to predominantly poor. In normal therapeutic dosis all three iron preparations showed no differences in tolerance. The ratio of side effects was similar to that after ingestion of placebo. In comparing the drug costs during a therapy leading to a real absorption of 1 g of iron the most effective iron(II)sulfate preparation S is 3.6 to 12.6 times cheaper than the compared trivalent preparations L and X. Therefore, there is no justification for the further production or introduction on the market of trivalent iron preparations.

Absorption↗
PubMed1977

[Clinical observations to characterize splenomegalic immunocytomas (author's transl)].

In ten patients with predominant splenomegaly the clinical development and progress of disease following the course of some years are described. The hematological values showed a moderate relative lymphocytosis with a slight but inconstant increase in white blood cell counts. A more or less small number of a morphologically distinctive population of plasmacytoid lymphocytes was an important diagnostic criterion and a decrease of at least one class of immunoglobulins could be shown. Only one patient presented a paraproteinemia (IgM). In the serum of six patients atypical unspecific antibodies were found. The histologic and cytologic feature of the spleens which were removed therapeutically was characterized by a mixed infiltration of lymphocytes and plasmocytoid or plasmacellular elements. By this pattern it was possible to classify these cases as lymphoplasmocytoid (resp. lymphoplasmocytic) immunocytomas according to the new Kiel-lymphoma-classification. From the clinical point of view they represented a subunit with markedly prevalent splenic proliferation. Liver and/or bone-marrow however showed in all cases primarily circumscribed infiltrations of pathognomonic cells or did develop them during the course of disease, even after splenectomy. According to the presented observations this disease is to be placed between chronic lymphocytic leukemia and M. Waldenström not only by pathological but also by clinical criteria.

Adult↗
PubMed1977

[Investigations of the bioavailability of iron from bi- and trivalent iron salts (author's transl)].

In a clinical pilot study, performed as an intraindividual comparison, 3 oral iron preparations, one bivalent iron sulfate (quick release stick capsule preparation) and two trivalent iron citrate complex preparations with different additives, were investigated on 9 healthy young male test persons by the iron absorption test (postabsorption serum iron concentration curves) in order to study the bioavailability of these drugs and their compatibility. Whereas both iron drugs proved equally compatible when administered in therapeutical doses, it was again confirmed that the enteral bioavailability of the ferrous iron sulfate is superior to that of the ferric iron complex preparation. According to these results the medication of ferric iron preparations seems once again to be proved unsuitable, trivalent iron having first to be reduced to bivalent absorbable iron, there however being usually not enough "reducing capacity" in the gastrointestinal tract to do this.

Adult↗
PubMedDate not supplied

Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD).

Coupling of anthracyclines to high-molecular-weight carriers may alter drug disposition and improve antitumor effects. We have performed a clinical phase I trial of doxorubicin coupled to dextran (70000 m.w.). The drug was administered as single dose i.v. every 21-28 days. Thirteen patients have received a total of 24 courses (median 2; range 1-3). At the starting dose of 40 mg/m2 doxorubicin equivalent (DOXeq), WHO grade IV thrombocytopenia was noted in 2/2 patients. WHO grade IV hepatotoxicity and WHO grade III cardiotoxicity were noted in a patient with preexisting heart disease. Five patients were treated with 12.5 mg/m2 DOXeq. Maximal toxicity at this dose level was WHO grade III thrombocytopenia and local phlebitis (WHO grade II) in 1/5 patients, elevation of alkaline phosphatase (WHO grade III) and WHO grade III vomiting in another patient. Subsequently, five patients received 20 mg/m2 DOXeq. Hepatotoxicity was noted in 5/5 patients (1 x WHO grade IV, 1 x WHO grade III). Thrombocytopenia was noted in 3/5 patients (1 x WHO grade IV, 2 x WHO grade III). At 12.5 mg/m2 DOXeq, a patient diagnosed with a malignant fibrous histiocytoma had stable disease for 4 months. Pharmacokinetic analyses of total and free doxorubicin were performed in plasma and urine. The maximum peak plasma concentration (ppc) for total DOX was 12.3 micrograms/ml at 40 mg/m2 DOXeq. The area under the plasma concentration time curve (AUC) ranged from 28.83-80.21 micrograms/ml*h with dose-dependent elimination half lives (t1/2 alpha: 0.02-0.87 h; t1/2 beta: 2.69-11.58 h; t1/2 gamma: 41.44-136.58 h).(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗